Advertisement


Judith Vick, MD Candidate, and Rachelle E. Bernacki, MD, on A New Clinical Tool: The “Surprise Question”

2015 Palliative Care in Oncology Symposium

Advertisement

Judith Vick, MD Candidate, of Johns Hopkins University School of Medicine, and Rachelle E. Bernacki, MD, of Dana-Farber Cancer Institute, discuss a tool that could help clinicians identify seriously ill patients who would benefit from conversations about their goals and values (Abstract 8).



Related Videos

Pain Management
Palliative Care
Symptom Management
Integrative Oncology

Lorenzo Cohen, MD, on Acupuncture and Other Nondrug Pain Management Techniques

Lorenzo Cohen, MD, of The University of Texas MD Anderson Cancer Center, discusses nonpharmacologic approaches to symptom control. Techniques such as acupuncture for managing pain and chemotherapy-induced nausea and vomiting, or yoga and meditation to help improve quality of life, can be safely integrated into oncology care.

Palliative Care

Kathleen Foley, MD, on Palliative Care in Low-Resource Settings

Kathleen Foley, MD, of Memorial Sloan Kettering Cancer Center, discusses the challenges of integrating palliative care in areas without sufficient resources or health-care infrastructure.

Palliative Care

Vicki Jackson, MD, MPH, on Effective Care Integration and the Comanagement Model

Vicki Jackson, MD, MPH, of Massachusetts General Hospital, summarizes her keynote lecture (plenary talk).

Symptom Management
Palliative Care

Lawrence H. Einhorn, MD, on CINV Clinical Trial Results: The Alliance A221301 Study

Lawrence H. Einhorn, MD, of Indiana University Simon Cancer Center, discusses the encouraging study findings on olanzapine for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy (Abstract 176).

Palliative Care
Symptom Management

Charles L. Loprinzi, MD, on Olanzapine for Prevention of CINV

Charles L. Loprinzi, MD, of the Mayo Clinic, discusses olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy (Abstract 176).

Advertisement

Advertisement




Advertisement